Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2018 Filed Aug 13, 2018 19:41 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 3,587 | $103.06 | $369,676.22 |
DisclosureSEC source: 0001209191-18-046384 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,707,597 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.00 to $103.17, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 17:28 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 24,620 | $103.22 | $2,541,325.64 |
DisclosureSEC source: 0001209191-18-045787 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,711,184 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.00 to $103.59, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 15:46 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 195,000 | $102.15 | $19,918,860.00 |
DisclosureSEC source: 0001209191-18-045625 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,735,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.75 to $102.59, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 18:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 15,797 | $100.18 | $1,582,559.26 |
DisclosureSEC source: 0001209191-18-045227 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,930,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.085 to $100.36, inclusive. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 18:31 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 174,203 | $99.52 | $17,337,379.37 |
DisclosureSEC source: 0001209191-18-045227 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,946,601 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.085 to $100.08, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 17:12 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 990 | $99.14 | $98,149.59 |
DisclosureSEC source: 0001209191-18-044671 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,120,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.14 to $99.15, inclusive. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 17:12 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 204,010 | $98.73 | $20,142,723.34 |
DisclosureSEC source: 0001209191-18-044671 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,121,794 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.12 to $99.09, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 26, 2018 Filed Jul 27, 2018 14:46 UTC |
TAI JACKSON PDirector
|
PurchaseCommon Stock | 2,168 | $95.22 | $206,436.96 |
DisclosureSEC source: 0000059478-18-000190 · wf-form4_153270278058574.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,228 F1 · security: This transaction was executed in multiple trades at prices ranging from $95.00 to $95.40. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2018 Filed Jul 27, 2018 17:58 UTC Amendment |
TAI JACKSON PDirector
|
PurchaseCommon Stock | 2,168 | $95.22 | $206,436.96 |
DisclosureSEC source: 0000059478-18-000192 · wf-form4a_153271428674754.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,228 F1 · security: This amendment is being filed to correctly report the footnote of the original Form 4 which was intended to be placed in column 4 Price. F2 · price: This transaction was executed in multiple trades at prices ranging from $95.00 to $95.40. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2018 Filed Feb 1, 2019 20:02 UTC Amendment |
TAI JACKSON PDirector
|
PurchaseCommon Stock | 1,568 | $95.22 | $149,304.96 |
DisclosureSEC source: 0000059478-19-000026 · wf-form4a_154905132771555.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,628 F1 · shares: The total represents a correction in the number of shares reported as purchased on the original Form 4. F2 · balance_after: The total represents the correct number of securities beneficially owned following the reported transaction. Beneficial share totals were incorrectly reported on two Forms 4 filed by the reporting person after his original Form 4 was filed. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 18:17 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 20,523 | $96.45 | $1,979,504.92 |
DisclosureSEC source: 0001209191-18-044020 · doc4.xml · nonDerivative · entry 4 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,325,804 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.31 to $96.62, inclusive. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 18:17 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 39,921 | $95.66 | $3,818,643.26 |
DisclosureSEC source: 0001209191-18-044020 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,346,327 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.30 to $96.17, inclusive. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 18:17 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 60,304 | $94.71 | $5,711,090.32 |
DisclosureSEC source: 0001209191-18-044020 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,386,248 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.30 to $95.295, inclusive. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 18:17 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 69,252 | $93.72 | $6,490,020.43 |
DisclosureSEC source: 0001209191-18-044020 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,446,552 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.30 to $94.295, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4) to this Form 4. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 15:47 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 30,132 | $93.43 | $2,815,353.29 |
DisclosureSEC source: 0001209191-18-043854 · doc4.xml · nonDerivative · entry 4 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,515,804 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.3468 to $93.62, inclusive. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 15:47 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 62,765 | $92.90 | $5,830,617.44 |
DisclosureSEC source: 0001209191-18-043854 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,545,936 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.3444 to $93.2798, inclusive. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 15:47 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 22,900 | $91.68 | $2,099,357.50 |
DisclosureSEC source: 0001209191-18-043854 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,608,701 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.331 to $92.2453, inclusive. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 15:47 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 69,203 | $90.76 | $6,280,656.67 |
DisclosureSEC source: 0001209191-18-043854 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,631,601 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.25 to $91.1614, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4) to this Form 4. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 19:36 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 61 | $89.07 | $5,433.27 |
DisclosureSEC source: 0000059478-18-000180 · wf-form4_153194258026996.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,350 Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 19:37 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 123 | $89.07 | $10,955.61 |
DisclosureSEC source: 0000059478-18-000181 · wf-form4_153194265991434.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,968 Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 19:59 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 109 | $89.07 | $9,708.63 |
DisclosureSEC source: 0000059478-18-000183 · wf-form4_153194397274797.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,211 Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 14:45 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 180,000 | $87.44 | $15,738,300.00 |
DisclosureSEC source: 0001209191-18-041946 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,700,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.08 to $87.705, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 15:13 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 170,000 | $86.62 | $14,725,740.00 |
DisclosureSEC source: 0001209191-18-041828 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,880,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.50 to $86.91, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 15:58 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000177 · wf-form4_153115186480621.xml · derivative · entry 3 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,862 Underlying: Common Stock · 2,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three installments, 2,394 on July 5, 2018, 2,394 on July 5, 2019, and 2,468 on July 5, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three installments, 2,394 on July 5, 2018, 2,394 on July 5, 2019, and 2,468 on July 5, 2020. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 15:58 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 752 | $86.51 | $65,055.52 |
DisclosureSEC source: 0000059478-18-000177 · wf-form4_153115186480621.xml · nonDerivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,642 Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 15:58 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Exercise / conversionCommon Stock | 2,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000177 · wf-form4_153115186480621.xml · nonDerivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:06 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 127 | $86.11 | $10,935.97 |
DisclosureSEC source: 0000059478-18-000171 · wf-form4_152952515835141.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,845 Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:09 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 63 | $86.11 | $5,424.93 |
DisclosureSEC source: 0000059478-18-000173 · wf-form4_152952533157811.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,289 Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:19 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 112 | $86.11 | $9,644.32 |
DisclosureSEC source: 0000059478-18-000175 · wf-form4_152952597012226.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,102 Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 16:39 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 180,000 | $86.65 | $15,597,720.00 |
DisclosureSEC source: 0001209191-18-038243 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,050,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.50 to $86.87, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 15, 2018 Filed Feb 1, 2019 18:54 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GiftCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000012 · wf-form5_154904726566943.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,568 Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 20:08 UTC |
Skovronsky DanielSVP, CSO, and Pres. LRL
|
PurchaseCommon Stock | 10,000 | $86.22 | $862,200.00 |
DisclosureSEC source: 0000059478-18-000167 · wf-form4_152900690318505.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,199 Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 15:00 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 107,698 | $86.31 | $9,295,414.38 |
DisclosureSEC source: 0001209191-18-037956 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,230,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.25 to $86.46, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 15:58 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 11,104 | $86.27 | $957,953.18 |
DisclosureSEC source: 0001209191-18-037648 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,338,502 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.25 to $86.38, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 12, 2018 Filed Feb 1, 2019 18:57 UTC |
Harrington Michael JSenior VP and General Counsel
|
GiftCommon Stock | 595 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000014 · wf-form5_154904745815105.xml · nonDerivative · entry 2 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,032 Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 18:46 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 51,198 | $86.38 | $4,422,636.83 |
DisclosureSEC source: 0001209191-18-037198 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,349,606 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.25 to $86.60, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 15:20 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 135,478 | $85.13 | $11,532,564.75 |
DisclosureSEC source: 0001209191-18-035460 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,400,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.37, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 18:25 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 39,522 | $85.31 | $3,371,661.34 |
DisclosureSEC source: 0001209191-18-034952 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,536,282 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.45, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 20:22 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
SaleCommon Stock | 25,000 | $85.00 | $2,125,000.00 |
DisclosureSEC source: 0000059478-18-000163 · wf-form4_152788452675858.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,534 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 8, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.00 to $85.03. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2018 Filed May 31, 2018 17:18 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 180,000 | $83.85 | $15,092,640.00 |
DisclosureSEC source: 0001209191-18-034303 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,575,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.61 to $84.015, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 29, 2018 Filed May 31, 2018 17:05 UTC |
Shaw ChristiSVP and Pres., Lilly Bio-Meds
|
SaleCommon Stock | 8,426 | $82.10 | $691,774.60 |
DisclosureSEC source: 0000059478-18-000159 · wf-form4_152778632353976.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 20:16 UTC Amendment |
Shaw ChristiSVP and Pres., Lilly Bio-Meds
|
SaleCommon Stock | 8,426 | $82.10 | $691,774.60 |
DisclosureSEC source: 0000059478-18-000161 · wf-form4a_152788418794578.xml · nonDerivative · entry 1 Shaw Christi · CIK 0001702473 · SVP and Pres., Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This amendment is being filed to add footnotes to the transaction. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 26, 2018. F1 · price: This amendment is being filed to add footnotes to the transaction. F3 · price: This transaction was executed in multiple trades at prices ranging from $81.73 to $82.10. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:21 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 133 | $81.83 | $10,883.39 |
DisclosureSEC source: 0000059478-18-000153 · wf-form4_152710683999376.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,455 Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:28 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 67 | $81.83 | $5,482.61 |
DisclosureSEC source: 0000059478-18-000155 · wf-form4_152710725159248.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,843 Read SEC document |
| May 21, 2018 Filed May 23, 2018 20:49 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 118 | $81.83 | $9,655.94 |
DisclosureSEC source: 0000059478-18-000157 · wf-form4_152710855289919.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 Read SEC document |
| May 15, 2018 Filed Feb 1, 2019 18:57 UTC |
Harrington Michael JSenior VP and General Counsel
|
GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000014 · wf-form5_154904745815105.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,627 Read SEC document |
| May 11, 2018 Filed May 14, 2018 18:29 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 140,000 | $81.97 | $11,475,940.00 |
DisclosureSEC source: 0001209191-18-029775 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,755,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.50 to $82.435, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 03, 2018 Filed May 3, 2018 20:34 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
SaleCommon Stock | 9,027 | $78.50 | $708,619.50 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · nonDerivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,458 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $78.32 to $78.60. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:26 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
Exercise / conversionRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000138 · wf-form4_152537915780405.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:26 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
Tax withholdingCommon Stock | 8,934 | $81.07 | $724,279.38 |
DisclosureSEC source: 0000059478-18-000138 · wf-form4_152537915780405.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,534 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.